MIF and tuberculosis: Overall, these results would help in understanding the role of this promoter variant in TB infection development and can aid in identifying new molecular targets by focusing on TB patients most likely to get benefit from the pharmacological targeting of MIF. Further well-designed and large sample studies are warranted to confirm the findings reported in this study.